ClinicalTrials.gg
Sign In

Drug

HY-0102 clinical trials

Also written HY-0102.

studies test it
3
open now
1
in phase 3
0
first study started
2022

Keep track of what changes. Save the HY-0102 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

HY-0102
3

Studies by the year they started

3 studies that test it; most in 2022 (1)

Studies that test HY-0102, by start year
YearStudies
20221
20231
20241

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
1
Pancreatic Neoplasms
1

Who runs them

Industry 3 · Other 0

Shanghai YingLi Pharmaceutical Co. Ltd. (2) · Shanghai HyaMab Biotech Co.,Ltd. (1)

Often tested with

Tested in the same studies.

TGF-beta Receptor 1 Kinase Inhibitor YL-13027 (1)

Studies

Open first, then newest update. How each study uses HY-0102 is read from its arms, and is right about nine times in ten.

Testing it · 3